• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Casdin Eli acquired 8,659,372 shares and was granted 39,527,671 shares

    12/21/21 5:20:26 PM ET
    $CMLT
    Get the next $CMLT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Casdin Eli

    (Last) (First) (Middle)
    C/O CASDIN CAPITAL LLC
    1350 AVENUE OF THE AMERICAS, SUITE 2600

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    EQRx, Inc. [ EQRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/17/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/17/2021 J(1) 8,659,372 A $0 8,659,372 I By CMLS Holdings III LLC(2)
    Common Stock 12/17/2021 A 34,527,671 A $0 43,187,043 I Casdin Partners Master Fund, L.P.(3)
    Common Stock 12/17/2021 A 5,000,000 A $10 48,187,043 I Casdin Partners Master Fund, L.P.(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Common Stock (1) 12/17/2021 J(1) 4,840,628 (1) (1) Common Stock 4,840,628 $0 0 I By CMLS Holdings III LLC(2)
    Class B Common Stock (1) 12/17/2021 J(1) 8,659,372 (1) (1) Common Stock 8,659,372 $0 0 I By CMLS Holdings III LLC(2)
    Warrants to purchase Class A Common Stock (right to buy) $11.5 12/17/2021 A(4) 8,110,001 04/09/2022 12/17/2026 Common Stock 8,110,001 (4) 8,110,001 I By CMLS Holdings III LLC(2)
    Explanation of Responses:
    1. In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475).
    2. The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
    3. The securities may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P. ("CPMF"), (Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund GP, LLC. ("CPGEF" and together with CPMF and CVOF, the "Casdin Funds") (ii) Casdin Partners GP, LLC, the general partner of CPMF, (iii) Casdin Venture Opportunities Fund GP, LLC, the general partner to CVOF, (iv) Casdin Private Growth Equity Funds GP, LLC, the general partner of CPGEF and (v) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. The shares held by Casdin Partners GP, LLC may be deemed to be indirectly beneficially owned by (i) Eli Casdin, the managing member of Casdin Partners GP, LLC. The address for the Casdin entities noted herein is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
    4. Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on April 9, 2022.
    /s/ Brian Emes, Attorney-in-Fact for Eli Casdin 12/21/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMLT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Casdin Eli acquired 8,659,372 shares, was granted 39,527,670 shares, converted options into 8,659,372 shares and disposed of 8,659,372 shares (Amendment)

    4/A - EQRx, Inc. (0001843762) (Issuer)

    12/23/21 8:47:17 PM ET
    $CMLT

    SEC Form 3: New insider Ah Equity Partners Lsv I, L.L.C. claimed ownership of 53,064,157 shares

    3 - EQRx, Inc. (0001843762) (Issuer)

    12/22/21 9:09:54 PM ET
    $CMLT

    SEC Form 3: New insider Ah Equity Partners Bio Ii, L.L.C. claimed ownership of 53,064,157 shares

    3 - EQRx, Inc. (0001843762) (Issuer)

    12/22/21 9:05:05 PM ET
    $CMLT

    $CMLT
    SEC Filings

    View All

    SEC Form EFFECT filed by CM Life Sciences III Inc.

    EFFECT - EQRx, Inc. (0001843762) (Filer)

    12/27/21 12:15:14 AM ET
    $CMLT

    SEC Form 424B3 filed by CM Life Sciences III Inc.

    424B3 - EQRx, Inc. (0001843762) (Filer)

    12/23/21 5:24:09 PM ET
    $CMLT

    SEC Form S-1 filed by CM Life Sciences III Inc.

    S-1 - EQRx, Inc. (0001843762) (Filer)

    12/20/21 9:17:41 PM ET
    $CMLT

    $CMLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices

    Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceedsCombined company to trade on Nasdaq Global Market under ticker "EQRX" NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (NASDAQ:CMLT, CMLTW, CMLTU))), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, and EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the completion of their business combination. The business combination was approved by CM Life S

    12/17/21 12:45:00 PM ET
    $CMLT

    $CMLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CM Life Sciences III Inc.

    SC 13D - EQRx, Inc. (0001843762) (Subject)

    12/27/21 4:31:28 PM ET
    $CMLT

    SEC Form SC 13D filed by CM Life Sciences III Inc.

    SC 13D - EQRx, Inc. (0001843762) (Subject)

    12/27/21 4:15:17 PM ET
    $CMLT

    SEC Form SC 13G filed by CM Life Sciences III Inc.

    SC 13G - CM Life Sciences III Inc. (0001843762) (Subject)

    12/10/21 4:41:04 PM ET
    $CMLT